NCT03277209 is a Phase 1 clinical trial of Plerixafor in Pancreas Cancer, sponsored by Weill Medical College of Cornell University.

Who is sponsoring NCT03277209?

NCT03277209 is sponsored by Weill Medical College of Cornell University.

What drugs are being tested in NCT03277209?

Interventions in NCT03277209: Plerixafor.

What condition does NCT03277209 study?

NCT03277209 studies Pancreas Cancer.

Is NCT03277209 still recruiting?

NCT03277209 is currently terminated. Last updated 2 March 2020.

Last reviewed 2020-03-02 · How we verify

NCT03277209

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas

Terminated Phase 1 Last updated 2 March 2020

What this trial tests

Phase 1 trial testing Plerixafor in Pancreas Cancer in 2 participants. Terminated before completion.

Timeline

25 July 2017

Primary endpoint
30 December 2019

30 December 2019

Quick facts

Lead sponsor	Weill Medical College of Cornell University
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	25 July 2017
Primary completion	30 December 2019
Estimated completion	30 December 2019
Sites	2 locations across United Kingdom, United States

Drugs / interventions tested

Plerixafor (plerixafor) — full drug profile →

Conditions studied

Pancreas Cancer — all drugs for Pancreas Cancer →

Sponsor

Weill Medical College of Cornell University

Who can join

18 and older, any sex, with Pancreas Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A dose escalation trial to assess the safety of plerixafor in patients with advanced pancreatic, high grade serous ovarian and colorectal cancer. To identify the proof of mechanism, by demonstrating alterations in T-cell tumour distribution, ideally associated with loss of tumour cells, measured by immunostaining, and changes in FDG uptake.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy.
Vilgelm AE, Richmond A. · · 2019 · cited 310× · PMID 30873179 · DOI 10.3389/fimmu.2019.00333
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses.
Anfray C, Ummarino A, Andón FT, Allavena P. · · 2019 · cited 222× · PMID 31878087 · DOI 10.3390/cells9010046
The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment.
Susek KH, Karvouni M, Alici E, Lundqvist A. · · 2018 · cited 177× · PMID 30319622 · DOI 10.3389/fimmu.2018.02159
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.
Daniel SK, Sullivan KM, Labadie KP, Pillarisetty VG. · · 2019 · cited 148× · PMID 30931508 · DOI 10.1186/s40169-019-0226-9
Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer.
Geng X, Chen H, Zhao L, Hu J, et al · · 2021 · cited 146× · PMID 34336821 · DOI 10.3389/fcell.2021.655152
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.
Zhang T, Ren Y, Yang P, Wang J, et al · · 2022 · cited 142× · PMID 36284087 · DOI 10.1038/s41419-022-05351-1
Immunotherapy for pancreatic cancer: Barriers and breakthroughs.
Torphy RJ, Zhu Y, Schulick RD. · · 2018 · cited 120× · PMID 30003190 · DOI 10.1002/ags3.12176

Verify or expand the search:

Other trials of Plerixafor

Trials testing the same drug.

NCT06851767 — Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy · Phase 1, PHASE2 · enrolling by invitation
NCT06207799 — Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Mu · Phase 2 · recruiting
NCT06414889 — Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Partic · Phase 1 · recruiting
NCT06158828 — Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML · Phase 1, PHASE2 · recruiting
NCT06325709 — Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease · Phase 1, PHASE2 · recruiting

Other recruiting trials for Pancreas Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting

Other Weill Medical College of Cornell University trials

Trials by the same sponsor.

NCT07485712 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2 · NA · not yet recruiting
NCT05811338 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1 · NA · not yet recruiting
NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT06818734 — Implementation of a Clinical Decision Support Tool for Postpartum Depression · NA · not yet recruiting
NCT07485725 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 3 · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03277209 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Weill Medical College of Cornell University
Last refreshed: 2 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03277209.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing